股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 健康之路股份有限公司 呈交日期: 2026年3月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02587 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,500,000,000 | USD | | 0.00002 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | | | 本月底結存 | | | 2,500,000,000 | USD | | 0.00002 | USD | | 50,000 | 本月底法定/註冊股本 ...

平衡与反应能力是预防跌倒、提升运动表现的核心要素，节目通过趣味测试，结合国民体质大数 据，展现中国人群的平衡与反应能力现状，并通过日常小游戏帮您提升平衡能力和反应速度。 ...

柔韧性是衡量身体机能的关键指标，却常常被忽视。节目聚焦国民柔韧性监测数据，无论是久坐族 还是运动爱好者，都能找回身体的柔韧与活力。 ...

Core Viewpoint - The announcement from Health Road (02587) marks a significant transition from a strategic investment phase to a value harvesting phase, with projected revenue of at least RMB 1.5 billion for the fiscal year 2025, representing over 25% year-on-year growth, and a net profit of at least RMB 50 million, indicating a historic turnaround [1] Group 1: Revenue and Profit Growth - The company expects its information technology services revenue to rise from RMB 296 million in 2024 to at least RMB 350 million in 2025, driven by the launch of big data technology services and AI products [1] - Health Road's AI software products are projected to contribute approximately RMB 30 million in scaled revenue by 2025, marking the transition of its AI strategy from concept validation to commercialization [1] Group 2: AI and Operational Efficiency - Health Road has developed a "digital employee" model that effectively addresses efficiency pain points in the healthcare industry, allowing for significant operational cost reductions [2] - The AI assistant for doctors reduces administrative burdens, while the AI health manager provides low-cost chronic disease management and reminders for patients, enhancing operational efficiency [2] Group 3: Market Opportunities - The shift of pharmaceutical companies' marketing budgets towards digital channels opens up a market potential estimated between RMB 800 billion to 1 trillion, as traditional marketing models face systemic upgrades [2] - Health Road's extensive network, connecting over 12,000 hospitals and more than 900,000 registered doctors, positions it as a natural platform for capturing this budget transition [3] Group 4: Content Services and Growth Drivers - The company's content services revenue is expected to surge from RMB 577 million in 2024 to at least RMB 800 million in 2025, becoming a core driver of sustained revenue and profit growth [3] - The implementation of tiered diagnosis and treatment policies and the push for digital health services in county-level medical institutions create a solid foundation for long-term growth [3] Group 5: Strategic Positioning and Future Outlook - Health Road is positioned as a foundational infrastructure in the digital healthcare sector, with a unique dual-end model that enhances its market valuation potential [4] - The anticipated profit turnaround in 2025 is seen as the beginning of value release, with AI technology expected to penetrate more specialized disease management areas and county-level scenarios [4]

智通财经APP了解到，在数字医疗行业普遍面临"AI落地难、变现难"的困境之时，健康之路自主研发的 AI软件产品在2025年即贡献约3000万元规模化收入，标志着健康之路的AI战略已从概念验证阶段正式 迈入商业化阶段。 得益于大数据技术服务及AI产品的推出，健康之路信息技术服务板块收入预计从2024年的2.96亿元攀升 至2025年的不少于3.5亿元。据智通财经APP了解，健康之路AI业务之所以能迅速获得市场认可，核心 则在于其独特的"数字员工"模式精准击中了医疗行业的效率痛点。 2月12日，健康之路（02587）发布的一则盈喜公告，犹如一道分水岭，清晰地划定了健康之路从战略投 入期向价值收获期的跨越。 根据公告，公司预期2025财年录得收入不少于人民币15亿元，同比增长超25%，净利润更是实现不少于 人民币5000万元的历史性反转。若深入剖析这则盈喜公告，最令人瞩目的并非单纯的利润数字，而是其 背后高质量的收入结构变化，尤其是AI盈利能力的商业化验证。 不同于通用大模型的"军备竞赛"，健康之路选择了一条更为务实的垂直应用路径，即通过对沉淀二十余 年的海量医患交互数据进行深度学习，健康之路构建了具备"高智商、高 ...

Group 1 - The provincial government emphasizes the importance of private enterprises and entrepreneurs, committing to create a favorable business environment and protect legal rights [2][3] - The government aims to strengthen policy support and optimize services for businesses, focusing on the "two health" practices in Henan [2] - Private entrepreneurs express gratitude for government support and show confidence in the economic development of Henan, pledging to contribute to high-quality growth [3] Group 2 - The meeting highlights the significance of the "14th Five-Year Plan" as a critical phase for the province's development [2] - Entrepreneurs are encouraged to align their business strategies with national and provincial development goals, enhancing the local economy [2] - Various private enterprise leaders participated in the discussion, sharing their commitment to invest in Henan and contribute to its economic progress [3]

Core Insights - A new "anchor point" in the global biopharmaceutical and digital health industry is emerging, with Open Evidence achieving a valuation of $12 billion in just 11 months, reflecting rapid market penetration [1][2] - Health Road (02587) in Hong Kong has transformed from a "registration tool" to an "AI-enabled medical ecosystem connector," mirroring Open Evidence's underlying logic and enhancing its commercial potential through a "Plus model" [1][2] Financial Performance - Health Road anticipates a revenue of at least RMB 1.5 billion for the full year of 2025, representing a year-on-year growth of at least 25%, with net profit expected to exceed RMB 50 million [1][5] - The company is projected to turn a profit in 2025, with a net profit recovery from a loss of RMB 269 million in 2024, driven by structural business changes and cost management [5][7] Business Model and Strategy - Both Open Evidence and Health Road focus on solving doctors' clinical efficiency pain points, establishing deep connections with healthcare professionals and leveraging vast amounts of medical interaction data [2][3] - Health Road's dual-end model, serving both doctors and patients, creates a comprehensive service ecosystem, enhancing its value ceiling and valuation potential compared to Open Evidence [3][4] Market Position and Competitive Advantage - Health Road's strong connection with the medical decision-making process allows it to capture a significant share of the pharmaceutical marketing budget transitioning to digital channels [3][4] - The company has developed a unique "doctor + assistant + AI" collaboration system, addressing the complexities of the Chinese healthcare system and enhancing its competitive moat [3][6] Growth Drivers - The digital marketing services, supported by a network of over 900,000 registered doctors, are becoming a key profit driver as pharmaceutical budgets shift towards high-quality academic content [5][6] - The real-world research (RWS) business is showing significant growth potential, with the company delivering hundreds of high-quality research reports to leading pharmaceutical companies [6][7] Future Outlook - 2025 is expected to be a pivotal year for Health Road, marking the commercialization of its AI business, with projected revenues of approximately RMB 30 million from AI software products [7] - As the company transitions from a traditional service provider to an AI-driven medical ecosystem platform, its valuation is anticipated to shift from "traditional service industry" to "AI platform enterprise" [7]

有色金属板块走弱，佳鑫国际资源跌超10%，中国有色矿业、力勤资源跌超8%。 医疗设备与服务板块走强，GUANZE MEDICAL涨超40%，健康之路涨近14%，万嘉集团涨超12%。 | 代码 | 名称 | 现价 | 涨跌幅 ▼ | 涨跌 | 换手率 | 5分钟涨跌幅 | 5日涨跌幅 | 王力 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2427 | GUANZE MEDICAL | 1.950 | 40.29% | 0.560 | 2.10% | 0.00% | 25.00% | | | 2587 | 健康之路 | 5.090 | 13.87% | 0.620 | 13.90% | 0.59% | 14.90% | | | 0401 | 万嘉集团 | 0.120 | 12.15% | 0.013 | 0.00% | 0.00% | 53.17% | | | 0932 | 顺腾国际控股 | 0.037 | 12.12% | 0.004 | 0.48% | 0.00% | 8.82% | | | 2252 | 微创机器人-B | 29.0 ...

Market Overview - The Hong Kong stock market experienced a decline on the last trading day of the Year of the Snake, with the Hang Seng Index falling by 1.72% or 465.42 points, closing at 26,567.12 points, and a total trading volume of 257.58 billion HKD [1] - The decline is attributed to weak fundamentals, concerns over tightening liquidity, and a decrease in the attractiveness of Hong Kong's unique market structure [1] Blue-Chip Performance - Zijin Mining (601899) led the blue-chip decline, dropping 7.64% to 41.58 HKD, contributing a loss of 33.26 points to the Hang Seng Index [2] - Other notable movements included Haidilao (06862) rising 3.13% to 17.15 HKD, and Sinopec (00386) falling 5.12% to 5.37 HKD, contributing a loss of 10.66 points to the index [2] Sector Performance - Large technology stocks continued to decline, with Alibaba-W dropping over 2% and Tencent Holdings nearly 1% [3] - Conversely, domestic large model stocks saw gains, with Zhiyuan (02513) increasing by 20.65% to 485 HKD and MiniMax-WP (00100) rising 15.65% to 680 HKD [3] Commodity Sector - The non-ferrous metals sector saw a significant drop, with China Nonferrous Mining (01258) down 5.27% to 14.91 HKD and Zijin Mining (02899) down 4.98% to 42.78 HKD [5] - The market reacted to unexpectedly strong U.S. employment data, which dampened expectations for an early interest rate cut by the Federal Reserve [5] AI and Technology Developments - The recent release of domestic AI models has led to a surge in related stocks, with significant advancements in AI capabilities being reported [4] - ByteDance's Seedance 2.0 model has gained popularity overseas, expected to lower the barriers for high-quality video content creation [4] Company Highlights - Haizhi Technology (02706) saw a remarkable debut, with shares rising 242.2% to 92.6 HKD, following a successful IPO that was oversubscribed by 5065.06 times [8] - Health Road (02587) reported expected revenue of no less than 1.5 billion RMB for 2025, marking a growth of at least 25% compared to the previous year [9] - MicroPort Robotics-B (02252) reported strong performance with over 200 global commercial orders for its core product, indicating a positive market reception [10]

智通财经APP获悉，蛇年末最后一个交易日，港股低开低走，午后跌幅略微收窄，尾盘三大指数悉数走 低。截止收盘，恒生指数跌1.72%或465.42点，报26567.12点，全日成交额为2575.78亿港元；恒生国企 指数跌1.55%，报9032.71点；恒生科技指数跌0.90%，报5360.42点。 中金指出，港股近期回调是基本面依然偏弱情况下，市场担忧流动性收紧和港股特色结构吸引力下降的 共同结果。在整体信用周期震荡甚至阶段走弱的情形下，市场指数层面空间有限(恒指基准点位28000- 29000)，机会主要来自景气结构或指数意外回撤。配置方向上，大思路依然是跟随信用扩张方向，在AI 科技、周期、消费和分红四大领域里，仍以AI科技和周期为主线，这也是当前信用扩张的主要方向。 蓝筹股表现 紫金矿业(02899)领跌蓝筹。截至收盘，跌7.64%，报41.58港元，成交额41.31亿港元，拖累恒指33.26 点。近期，避险情绪上升叠加大宗商品风险抛售等市场氛围烘托，有色金属今日全线回落。兴业证券认 为，有色短期将进入商品降波交易，改节奏但不改方向。一季度后端的旺季基本面具备支撑，若年后宏 观预期端不出现方向性扭转的前提 ...